Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in ...

By Michael Erman May 29 (Reuters) - Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed ...

Teclistamab (Tecvayli) monotherapy significantly improved survival compared with standard therapies in patients with multiple myeloma who had received up to three previous lines of therapy, the phase ...

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to ...

Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically ...

In this analysis, researchers evaluated data from a subgroup of US patients enrolled in the phase 2 MagnetisMM‐3 study.

MajesTEC-9 randomized 593 patients (median age 70; median two prior lines) to teclistamab or investigator’s choice PVd or Kd; 80% lenalidomide-refractory, 85% anti-CD38–refractory. Interim analysis ...

The efficacy of teclistamab, a bispecific antibody targeting B-cell maturation antigen and CD3, as early-line monotherapy in relapsed or refractory multiple myeloma is unclear. We randomly ...

New pill offers hope for patients with incurable blood cancer - About 6,200 people every year in the UK are diagnosed with ...

An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are most likely to benefit from specific therapies, including immunotherapy and stem ...

Patients battling an incurable blood cancer could live significantly longer without their disease progressing, thanks to a new once-daily pill that may soon be added to existing NHS treatments, ...

MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of Johnson & Johnson’s TECVAYLI® as early as second line1TECVAYLI® delivered deep and durable responses, with nearly ...